Percorrer por autor "Sanchez-Ayala, Alfonso"
A mostrar 1 - 4 de 4
Resultados por página
Opções de ordenação
- Beauty choices : uncovering the profile of who opts for aesthetic proceduresPublication . Agrizzi, Rafaela Rocha; Peroni, Matheus Bellanda; Gonçalves-Soares, Leticia Machado; Carbone, Ana Claudia; Câmara-Souza, Mariana Barbosa; Sanchez-Ayala, Alfonso; Manso, Ana Cristina; Canales, Giancarlo De la TorreBackground: The demand for aesthetic procedures has increased, driven by advances in aesthetic therapies. Therefore, understanding the factors that influence individuals to undergo aesthetic procedures is important. This study aimed to assess the profile of patients that received or did not receive aesthetic procedures. Methods: This cross-sectional study enrolled 834 female participants aged between 18 and 65 years which were divided in two groups: yes to aesthetic procedures (YAP) and no to aesthetic procedures (NAP). Participants were instructed to fill out a form that included sociodemographic questions, a question regarding performing or not aesthetic procedures and the Portuguese validated versions of five FACE-Q scales. Data were collected electronically from October 2023 to February 2025. For group comparison for continuous variables, the Yuen test was used and Fisher's exact test for categorical variables. Multivariate logistic regression was also performed to assess the influence of variables in performing aesthetic procedures. Results: The sociodemographic data showed group differences in age, education and marital status and income (p < 0.001). Botulinum toxin type A was the most common minimally invasive procedures reported by the participants. Also, volunteers of the YAP group showed greater self-perception and concern about ageing (FACE-Q1 ageing appraisal) (p=0.001). Multivariate logistic regression analysis showed that marital and education status, income and FACE-Q1 influence the decision of performing aesthetic procedures. Conclusion: Women of higher educational level, divorce, with higher income and that present higher concerns about ageing are linked to a greater likelihood of undergoing facial aesthetic procedures.
- Comparing ready-to-use and powder abobotulinumtoxinA for glabellar lines : a randomized, controlled, triple-blinded clinical trialPublication . Silva Junior, Silvio Ventura da; Neves, Maria Luiza Boechat Borges; Sanchez-Ayala, Alfonso; Cebola, Pedro Miguel Teixeira Carvas; Carbone, Ana Claudia; Câmara-Souza, Mariana Barbosa; Poluha, Rodrigo Lorenzi; Canales, Giancarlo De la TorreBackground: Botulinum toxin A (BoNT-A) is the most used procedure to treat glabellar lines; however, limited data exist about the effectiveness of ready-to-use BoNT-A (RTUaboBoNT-A) for this indication. Aims: This study compared the efficacy, durability, and safety of RTUaboBoNT-A for moderate and severe glabellar wrinkles. Methods: This randomized triple-blinded trial included 38 male volunteers aged between 25 and 50 years. Participants were randomly divided into two groups: abobotulinumtoxinA (aboBoNT-A, n = 18) and RTUaboBoNT-A (n = 20). Groups received 10 U for procerus muscle and 20 U for the corrugator muscle. Assessed variables included, electromyography activity (EMG), Merz 5-point glabellar lines scale, FACE-Q appraisal for lines between the eyebrows and Visual Analogue Scale for pain intensity. Assessments were performed before and 1, 2, 3, and 4 months after injections. For differences in EMG and satisfaction scores, the two-way repeated-measures ANOVA and Bonferroni's post hoc analyses were conducted. Wrinkle severity scores were analyzed with the chi-squared test. Results: Inter-group comparisons revealed no significant differences in EMG scores in all assessed periods for the corrugator supercili (p = 0.11) and the procerus muscles (p = 0.93); for severity of glabellar lines, no significant differences were also found in all follow-ups for rest (p = 0.737) and contracted position (p = 0.390), as well as for satisfaction with the treatments. However, the RTUaboBoNT-A group presented higher levels of pain intensity during the injection procedure (p = 0.01). Conclusion: The RTUaboBoNT-A and aboBoNT-A are comparable in efficacy, durability, and safety.
- Exploring botulinum toxin’s impact on masseter hypertrophy : a randomized, triple-blinded clinical trialPublication . Nobre, Bryanne Brissian de Souza; Rezende, Luciana; Câmara-Souza, Mariana Barbosa; Sanchez-Ayala, Alfonso; Blass, Rodrigo; Carbone, Ana Claudia; Manso, Ana Cristina; Ernberg, Malin; Christidis, Nikolaos; Canales, Giancarlo De la TorreThe present study aimed to assess the effectiveness and functional adverse effects of a single and multiple injections of botulinum toxin A (BoNT-A) for masseter hypertrophy (MH). Twenty-six women complaining about lower third facial enlargement due to MH, received 75 U of BoNT-A (abobotulinum toxin) in each masseter muscles. After 3 months, patients were randomly assigned to receive a second treatment session of Saline Solution: (G1; n = 11) or BoNT-A: (G2; n = 12). Muscle thickness (ultrasound), electrical activity (electromyography; EMG), masticatory performance, and subjective perception of MH were evaluated. Follow-up was performed at 1, 3 and 6 months. Muscle thickness, EMG activity, and masticatory performance were analyzed using ANOVA two-way and Sidak test as post-hoc. Masticatory performance was analyzed by the Friedman’s test and Mann–Whitney test. Regarding inter-groups comparisons, there was a significant decrease in the left masseter muscle thickness in the G2 group at the 6 month follow-up (p < 0.02). For EMG, significant differences were evident at the 6 month assessment, with higher masseter activity for G1 (p < 0.05). For masticatory performance, no significant differences were observed throughout the study (p > 0.05) and a higher improvement in subjective perception of MH was observed in the 1 month follow-up for G2 (p < 0.05). In conclusion, BoNT-A is effective for MH, however multiple injections cause functional adverse effects in masseter muscle.
- Is ready-to-use abobotulinumtoxinA more effective than OnabotulinumtoxinA for glabellar lines? A randomized, controlled, triple-blinded clinical trialPublication . Gonçalves, Jacqueline Rosa; Valesan, Ligia Figueiredo; Shishido, Ana Claudia Laureano Navarro; Sanchez-Ayala, Alfonso; Carbone, Ana Claudia; Câmara-Souza, Mariana Barbosa; Canales, Giancarlo De la TorreBackground: Most commercially available botulinum toxin A (BoNT-A) formulations are lyophilized or vacuum-dried powders requiring reconstitution. Recently a ready-to-use formulation (RTUaboBoNT-A) has been introduced. Although its efficacy in reducing glabellar lines has been reported, comparative data with powder onabotulinumtoxinA (OnaBoNT-A) remain limited. Aims: To evaluate the efficacy, durability, and safety of RTUaboBoNT-A compared with OnaBoNT-A for moderate to severe glabellar wrinkles: Methods: Forty women (25–50 years) were randomly allocated to receive either OnaBoNT-A (n = 20) or RTUaboBoNT-A (n = 20) at equivalent doses in the procerus and corrugator muscles. Outcomes included Electromyography activity (EMG), Merz 5-point glabellar lines scale, FACE-Q satisfaction scores, perceived age and pain intensity (VAS). Assessments were performed at baseline and 1, 2-, 3-, 4- and 5-months post-injection. Statistical analysis included two-way repeated-measures ANOVA with Bonferroni's post hoc, chi-squared tests and independent Student's t-tests. Results: No significant intergroup differences were observed in EMG activity of the assessed muscles across follow-ups (p > 0.05). Glabellar lines severity was comparable between groups at rest and maximum contraction throughout the study (p > 0.05). Higher satisfaction scores were observed at 2-months in the OnaBoNT-A group (p = 0.01). Pain during injection was greater with RTUaboBoNT-A (p = 0.02). No intergroup differences were found in perceived age (p > 0.05). Conclusion: The RTUaboBoNT-A demonstrated similar efficacy, durability, and safety profile to OnaBoNT-A for the treatment of glabellar lines. With minor differences in satisfaction and injection disconfort.